Skip to main content
SpringerLink
Log in

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

  • Original Article
  • CPT-11, lrinotecal Topotecan, Camptotheci Topoisomerases, Xenograf
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

The efficacy of protracted schedules of therapy of the topoisomerase I inhibitors 9-dimethylaminomethyl-10-hydroxycamptothecin (topotecan) and 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (irinotecan; CPT-11) were evaluated against a panel of 21 human tumor xenografts derived from adult and pediatric malignancies. Tumors included eight colon adenocarcinomas, representing an intrinsically chemorefractory malignancy, six lines derived from childhood rhabdomyosarcoma (three embryonal, three alveolar) representing a chemoresponsive histiotype, sublines of rhabdomyosarcomas selected in vivo for resistance to vincristine and melphalan, and three pediatric brain tmors. All tumors were grown at the subcutaneous site. Topotecan was administered by oral gavage 5 days per week for 12 consecutive weeks. The maximum tolerated dose (MTD) was 1.5 mg/kg per dose. Irinotecan was given by i.v. administration daily for 5 days each week for 2 weeks [(d×5)2] (one cycle of therapy), repeated every 21 days. The MTD for three cycles was 10 mg/kg per dose. Treatment was started against advanced tumors. Topotecan caused a high frequency of objective regressions in one of eight colon tumor lines, whereas irinotecan caused complete regressions (CR) of all tumors in three colon lines and a high frequency of CRs in three additional lines. Both drugs demonstrated similar activity against rhabdomyosarcoma xenografts. Topotecan caused CR of all tumors in four of six lines, and irinotecan in five of six lines evaluated. Both agents retained full activity against tumors selected for primary resistance to vincristine, but only irinotecan retained activity against a tumor selected for primary resistance to melphalan. Both agents demonstrated good activity against brain tumor xenografts with irinotecan causing CR in two of three lines and topotecan inducing CR in one of three lines. Results indicate that low-dose protracted schedules of daily administration of these topoisomerase I inhibitors is either equi-effective or more efficacious than more intense shorter schedules of administration reported previously.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wang JC (1985) DNA topoisomerases. Annu Rev Biochem 54: 665

    Google Scholar 

  2. Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MJ, McCabe FL, Faucette LF, Johnson RK, Hertzberg RP (1990) Synthesis of water soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 34: 98

    Google Scholar 

  3. Gottlieb JA, Luce J (1972) Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56: 103

    Google Scholar 

  4. Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB (1970) Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother Rep 54: 461

    Google Scholar 

  5. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG (1972) Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95

    Google Scholar 

  6. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Pomesil M (1989) DNA topoisomerase 1-targeted chemotherapy of human colon cancer xenografts. Science 246: 1046

    Google Scholar 

  7. Pantazis P, Hinz HR, Mendoza JT, Kozielski AS, Williams LJ, Stehlin JS Jr, Giovanella BC (1992) Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52: 3980

    Google Scholar 

  8. Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA (1992) Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 31: 229

    Google Scholar 

  9. Friedman HS, Houghton PJ, Schold SC, Keir S, Bigner DD (1994) Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 34: 171

    Google Scholar 

  10. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-1-carbonyloxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944

    Google Scholar 

  11. Matsuzaki T, Yokokura T, Mutai M, Tsuruo T (1988) Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21: 308

    Google Scholar 

  12. Bissery MC, Mathieu-Boué A, Lavelle F (1991) Preclinical evaluation of CPT-11, a camptothecin derivative. Proc Am Assoc Cancer Res 33: A2389

    Google Scholar 

  13. Bissery MC, Mathieu-Boué A, Lavelle F (1992) Experimental activity of CPT-11 in vitro and in vivo. Ann Oncol 3 [Suppl 1]: A093

    Google Scholar 

  14. Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T, Matsumoto K (1991) Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28: 192

    Google Scholar 

  15. Houghton PJ, Cheshire PJ, Hallman JC, Bissery MC, Mathieu-Boué, A, Houghton JA (1993) Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross resistance in vivo in tumors with acquired resistance to the topoisomerase inhibitor 9-dimethylaminomethyl-10-hydoxycamptothecin Cancer Res 53: 2823

    Google Scholar 

  16. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T (1988) Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 21: 71

    Google Scholar 

  17. Taguchi T, Wakui A, Hasegawa K (1990) Phase I clinical study of CPT-11. Gan To KagakuRyoho 17: 115

    Google Scholar 

  18. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M (1992) CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10: 1225

    Google Scholar 

  19. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M, Ito Y, Morishima Y, Yokomaku S, Ota K (1990) An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8: 1907

    Google Scholar 

  20. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16

    Google Scholar 

  21. Masuda N, Fukuoka M, Kudoh, S, Kusunoki Y, Matsui K, Takifuji N, Nakagawa K, Tamanoi M, Nitta T, et al (1993) Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 68: 777

    Google Scholar 

  22. Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Nakagawa K, Hirashima T, Tamanoi M, Nitta T, Yana T, et al (1994) Phase I study of irinotecan and cisplatin with granulocyte colony stimulating factor support for advanced non-small cell lung cancer. J Clin Oncol 12: 90

    Google Scholar 

  23. Shinkai T, Arioka H, Kunikane H, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Oshita F, Nishio M, Karato A, et al (1994) Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose vindesine in advanced non-small cell lung cancer. Cancer Res 54: 2636

    Google Scholar 

  24. Shimada Y, Sasaki Y, Sugano K, Shirao K, Kondo H, Yokota T, Saito D, Tamura T, Ohe Y, Shinaki T, et al (1993) Combination phase I study of CPT-11 (irinotecan) combined with continuous infusion of 5-fluorouracil (5FU) in metastatic colorectal cancer. Proc Am Assoc Clin Oncol 12: A575

    Google Scholar 

  25. Negoro S, Fukuoka M, Masuda N, Kusunoki Y, Matsui K, Kudoh S, Takifuji N, Nakagawa K, Hirashima T, Tamanoi M, et al (1993) Phase I study of irinotecan (CPT-11) and etoposide (E) with G-CSF in advanced lung cancer. Proc Am Assoc Clin Oncol 12: A331

    Google Scholar 

  26. Houghton PJ, Houghton JA, Myers L, Cheshire PJ, Howbert JJ, Grindey GB (1989) Evaluation of N-(5-indanylsulfonyl)-N′-(4-chlorophenyl) urea against xenografts of pediatric rhabdomyosarcoma. Cancer Chemother Pharmacol 25: 84

    Google Scholar 

  27. Houghton JA, Houghton PJ, Webber BL (1982) Growth and characterization of childhood rhabdomyosarcomas as xenografts. J Natl Cancer Inst 68: 437

    Google Scholar 

  28. Houghton JA, Houghton PJ, Hazelton BJ, Douglass EC (1985) In situ selection of a human rhabdomyosarcoma resistant to vincristine with altered β-tubulins. Cancer Res 45: 2706

    Google Scholar 

  29. Hazelton BJ, Houghton JA, Parham DM, Douglass EC, Torrance PM, Holt H, Houghton PJ (1987) Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res 47: 4501

    Google Scholar 

  30. Douglass EC, Valentine M, Etcubanas E, Parham DM, Webber BC, Houghton JA, Houghton PJ, Green AA (1987) A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet 45: 148

    Google Scholar 

  31. Houghton JA, Cook RL, Lutz PJ, Houghton PJ (1984) Childhood rhabdomyosarcoma xenografts: response to DNA interacting agents and agents used in current clinical therapy. Eur J Cancer Clin Oncol 20:955

    Google Scholar 

  32. Houghton JA, Cook RL, Lutz PJ, Houghton PJ (1985) Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma. Cancer Treat Rep 69: 91

    Google Scholar 

  33. Horton JK, Houghton PJ, Houghton JA (1987) Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard. Cancer Res 47: 6288

    Google Scholar 

  34. Houghton JA, Taylor DM (1978) Growth characteristics of human colorectal tumors during serial passage in immune-deprived mice. Br J Cancer 37: 213

    Google Scholar 

  35. Houghton JA, Taylor DM (1978) Maintenance of biological and biochemical characteristics of human colorectal tumors during serial passage in immune-deprived mice. Br J Cancer 37: 199

    Google Scholar 

  36. Houghton JA, Houghton PJ (1987) The suitability and use of human tumor xenografts. In: Kallman RF (ed) Rodent tumor models in experimental cancer therapy. Pergamen Press, New York, p 199

    Google Scholar 

  37. Houghton JA, Houghton PJ (1980) On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xenografts maintained in immune-deprived mice. Cancer 45: 1159

    Google Scholar 

  38. Houghton PJ, Horton JK, Houghton JA (1991) Drug sensitivity and resistance in the xenograft model. In: Maurer HM, Ruyman FB, Pochedly C (eds) Rhabdomyosarcomas and related tumors in children and adolescents. CRC Press, Boston, p 188

    Google Scholar 

  39. Friedman HS, Colvin OM, Skapek SX, Ludeman SM, Elion GB, Schold SC Jr, Jacobsen PF, Mulbaier LH, Bigner DD (1988) Experimental chemotherapy of human medulloblastom cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 48: 4189

    Google Scholar 

  40. Del-Bino GD, Lassota P, Darzynkiewicz Z (1991) The s-phase cytotoxicity of comptothecin. Exp Cell Res 193: 27

    Google Scholar 

  41. Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Herait P, Gandia D (1994) Irinotecan (CPT-11) high dose escalation with intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86: 446

    Google Scholar 

  42. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucoronidation with diarrhea. Cancer Res 54: 3723

    Google Scholar 

  43. DeMorais SMF, Wells PG (1989) Enhanced acetominophen toxicity in rats with bilirubin glucoronyl transferase deficiency. Hepatology 10: 163

    Google Scholar 

  44. Hjelle JJ (1986) Hepatic UDP-glucoronic acid regulation during acetominophen biotransformation in rats. J Pharmacol Exp Ther 237: 750

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Pharmacology, St. Jude Children's Research Hospital, 332 N. Lauderdale, 38101, Memphis, TN, USA

    Peter J. Houghton, Pamela J. Cheshire, James D. Hallman II, Lois Lutz, Mary K. Danks & Janet A. Houghton

  2. Department of Pediatrics, Duke University Medical Center, Durham, NC, USA

    Henry S. Friedman

Authors
  1. Peter J. Houghton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pamela J. Cheshire
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James D. Hallman II
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lois Lutz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Henry S. Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mary K. Danks
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Janet A. Houghton
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported in part by PHS awards CA32613, CA23099, CA60178, NS30245, Cancer Center Support CORE Grant CA21765, American Cancer Society grant DHR 67E, and by American Lebanese Syrian Associated Charities (ALSAC).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Houghton, P.J., Cheshire, P.J., Hallman, J.D. et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol. 36, 393–403 (1995). https://doi.org/10.1007/BF00686188

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686188

Key words

Search

Navigation